Efficacy of Fluoxetine in Reducing Ictal Hypoventilation in Patients With Partial Epilepsy

Patients who consent to participate in the study will come to the clinic one week prior to
the scheduled date of hospitalization in the Epilepsy Monitoring Unit (EMU). At this visit
a complete physical examination including vital signs and complete neurological examination,
mental status, cranial nerves, motor examination, deep tendon reflexes, sensory examination,
coordinator and gait will be performed. Baseline laboratory studies including complete
blood count, serum electrolytes, renal and liver function studies and serum pregnancy test
for female patients will also be performed. Study medication will be dispensed at this
visit.

Patients will be randomized to receive either 20 mg/day of fluoxetine (one pill) or placebo
(one pill), to be started one week prior to the scheduled hospital admission date. The dose
will be increased to two pills per day on day 1 of hospitalization bringing the total dose
of fluoxetine to 40 mg/day in patients randomized to receive this medication. On the day of
discharge from the hospital, the study medication will be reduced to 1 pill per day and the
patient will be instructed to stop the medication one week following discharge. A follow-up
clinic visit for the patient will be scheduled 1 month following hospital discharge, as is
the usual protocol for patients undergoing VET at our institution.

Inclusion Criteria:

1. Adult patients with temporal lobe epilepsy, aged 18-65.

2. Medical intractability of seizures such that VET to determine candidacy for epilepsy
surgery is determined to be clinically appropriate for the patient by the primary
treating epileptologist.

3. Intelligence Quotient >70.

4. Native English speaker or adequate fluency in English to provide informed consent.

5. Female patients of child-bearing potential must be using an acceptable method of
contraception, including abstinence.

Exclusion Criteria:

1. Progressive neurological disease.

2. Severe depression, bipolar disease or psychosis.

3. History of suicidal ideation or intent.

4. Clinically significant concurrent medical illness, including hepatic or renal
insufficiency and diabetes.

5. Pregnant or lactating women.

6. Current heavy alcohol or illicit drug use.

7. Patients already taking fluoxetine or other selective serotonin reuptake inhibitors
(SSRIs).

8. Concurrent use of monoaminoxidase inhibitors, antipsychotic agents, antidepressant
agents other than SSRIs or frequent use of triptan agents.

9. History of a previous allergic reaction or adverse effects with SSRIs.

10. History of serotonin syndrome.